+

WO2000068399A3 - Vector-mediated delivery of integrating transposon sequences - Google Patents

Vector-mediated delivery of integrating transposon sequences Download PDF

Info

Publication number
WO2000068399A3
WO2000068399A3 PCT/US2000/012827 US0012827W WO0068399A3 WO 2000068399 A3 WO2000068399 A3 WO 2000068399A3 US 0012827 W US0012827 W US 0012827W WO 0068399 A3 WO0068399 A3 WO 0068399A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector
integrating
mediated delivery
transposon sequences
transposase
Prior art date
Application number
PCT/US2000/012827
Other languages
French (fr)
Other versions
WO2000068399A2 (en
Inventor
R Scott Mcivor
Perry B Hackett
Estuardo Aguilar-Cordova
Original Assignee
Univ Minnesota
Baylor College Medicine
R Scott Mcivor
Perry B Hackett
Aguilar Cordova Estuardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Baylor College Medicine, R Scott Mcivor, Perry B Hackett, Aguilar Cordova Estuardo filed Critical Univ Minnesota
Priority to CA002373121A priority Critical patent/CA2373121A1/en
Priority to JP2000616365A priority patent/JP2002543792A/en
Priority to AU47110/00A priority patent/AU4711000A/en
Publication of WO2000068399A2 publication Critical patent/WO2000068399A2/en
Publication of WO2000068399A3 publication Critical patent/WO2000068399A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides non-integrating vectors, preferably non-integrating viral vectors, that include a transposon, preferably a transposon and nucleotide sequences encoding a transposase, and most preferably a transposon, nucleotide sequences encoding a transposase, and nucleotide sequences encoding a polypeptide that regulates expression of the transposase. Also provided are methods of using the non-integrating vectors.
PCT/US2000/012827 1999-05-11 2000-05-11 Vector-mediated delivery of integrating transposon sequences WO2000068399A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002373121A CA2373121A1 (en) 1999-05-11 2000-05-11 Vector-mediated delivery of integrating transposon sequences
JP2000616365A JP2002543792A (en) 1999-05-11 2000-05-11 Supply and integration of transposon sequences by vector
AU47110/00A AU4711000A (en) 1999-05-11 2000-05-11 Vector-mediated delivery of integrating transposon sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13356999P 1999-05-11 1999-05-11
US60/133,569 1999-05-11

Publications (2)

Publication Number Publication Date
WO2000068399A2 WO2000068399A2 (en) 2000-11-16
WO2000068399A3 true WO2000068399A3 (en) 2001-01-25

Family

ID=22459260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012827 WO2000068399A2 (en) 1999-05-11 2000-05-11 Vector-mediated delivery of integrating transposon sequences

Country Status (4)

Country Link
JP (1) JP2002543792A (en)
AU (1) AU4711000A (en)
CA (1) CA2373121A1 (en)
WO (1) WO2000068399A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466948T1 (en) 1997-03-11 2010-05-15 Univ Minnesota DNA-BASED TRANSPOSON SYSTEM FOR INTRODUCING NUCLIC ACID INTO A CELL'S DNA
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
CA2692501C (en) 2007-07-04 2017-10-10 Max-Delbrueck-Centrum Fuer Molekulare Medizin Hyperactive variants of the transposase protein of the transposon system sleeping beauty
CN105154473B (en) * 2015-09-30 2019-03-01 上海细胞治疗研究院 A kind of transposon integration system of highly effective and safe and application thereof
CN105481984B (en) * 2015-12-03 2020-09-22 上海细胞治疗研究院 Transposase for efficiently mediating exogenous gene integration and application thereof
GB201705927D0 (en) * 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
WO2020014528A1 (en) * 2018-07-13 2020-01-16 The Regents Of The University Of California Retrotransposon-based delivery vehicle and methods of use thereof
CN110734929B (en) * 2019-11-14 2022-11-22 南通大学 A transposon-mediated efficient non-viral eukaryotic cell stable transfection method
US20250051735A1 (en) 2021-12-22 2025-02-13 Vanderbilt University Next generation transpososomes
WO2025002240A1 (en) * 2023-06-29 2025-01-02 The University Of Hong Kong Method for controllable transcription in liver or liver cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485701A1 (en) * 1990-09-28 1992-05-20 American Cyanamid Company Insertion of DNA by modified transposons
WO1996001313A1 (en) * 1994-07-01 1996-01-18 Hermann Bujard Tetracycline-regulated transcriptional modulators
WO1996040892A1 (en) * 1995-06-07 1996-12-19 Basf Ag Tetracycline regulated transcriptional modulators with altered dna binding specificities
EP0756007A2 (en) * 1995-06-30 1997-01-29 Ajinomoto Co., Ltd. Method of amplifying gene using artificial transposon
WO1997015679A1 (en) * 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
WO1997029202A1 (en) * 1996-02-09 1997-08-14 Het Nederlands Kanker Instituut Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
WO1998040510A1 (en) * 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
WO1999025817A2 (en) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485701A1 (en) * 1990-09-28 1992-05-20 American Cyanamid Company Insertion of DNA by modified transposons
WO1996001313A1 (en) * 1994-07-01 1996-01-18 Hermann Bujard Tetracycline-regulated transcriptional modulators
WO1996040892A1 (en) * 1995-06-07 1996-12-19 Basf Ag Tetracycline regulated transcriptional modulators with altered dna binding specificities
EP0756007A2 (en) * 1995-06-30 1997-01-29 Ajinomoto Co., Ltd. Method of amplifying gene using artificial transposon
WO1997015679A1 (en) * 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
WO1997029202A1 (en) * 1996-02-09 1997-08-14 Het Nederlands Kanker Instituut Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
WO1998040510A1 (en) * 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
WO1999025817A2 (en) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IVICS Z ET AL: "MOLECULAR RECONSTRUCTION OF SLEEPING BEATUY A TC1-LIKE TRANSPOSON FROM FISH, AND ITS TRANSPOSITION IN HUMAN CELLS", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 91, November 1997 (1997-11-01), pages 501 - 510, XP000700195, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
CA2373121A1 (en) 2000-11-16
JP2002543792A (en) 2002-12-24
AU4711000A (en) 2000-11-21
WO2000068399A2 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000068399A3 (en) Vector-mediated delivery of integrating transposon sequences
WO2001053312A8 (en) Novel nucleic acids and polypeptides
AU6020598A (en) Dna sequences, vectors, and fusion polypeptides for secretion of polypeptides infilamentous fungi
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2003048202A3 (en) Nf-kappab activating genes
WO1997038010A3 (en) Fusogenic liposomes
WO2001044284A3 (en) Chimeric natriuretic peptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2002072616A3 (en) Transfection complexes
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2003070751A3 (en) Partial peptide mimetics and methods
GB2368846B (en) Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
WO2001004331A3 (en) Enhanced expression of proteins using gfp
AU2001286302A1 (en) High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor
WO2002044340A3 (en) Novel nucleic acids and polypeptides
IL139604A0 (en) Novel peptides
WO2002068673A3 (en) Hin-1, a tumor suppressor gene
AU2626699A (en) Self-replicating vector for dna immunization against hiv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2373121

Country of ref document: CA

Ref country code: CA

Ref document number: 2373121

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616365

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载